Byoung-Chan Kim

Chief Executive Officer

HealthBiome Inc

Dr Byoung-Chan Kim received his B.S, M.S, and Ph.D. from Yonsei University (Department of Biotechnology) and is currently serving as Chief Executive Officer of HealthBiome Inc. His research interests include: isolation, taxonomic classification & fermentation of strict anaerobic bacteria. Dr Kim’s past roles include Professor of Microbiology at UMass, USA, and Senior/Principal Investigator at the Korea Research Institute of Bioscience & Biotechnology (KRIBB). 

Maryanne O'Hara

Author

AMR Patient Advocate

Lesley Ogilvie

Scientific Programme Officer

Global AMR R&D Hub

Cary Adams

CEO

The Union for International Cancer Control

Cary Adams

CEO

The Union for International Cancer Control

Fleur Anderson

Member Of Parliament

House of Commons

Yuri Martina

CMO

Destiny Pharma

Tim Walsh

Research Director

Oxford University

Professor Tim Walsh has been studying antimicrobial resistance (AMR) mechanisms for over 25 years and publishes regularly in Nature and Lancet journals. Notably, in his career he has discovered and named two of the most notorious antibiotic resistant genes – NDM-1 and MCR-1. His work also helped discover the mobile tigecycline gene (tetX variant).

Vikas Aggarwal

Regional Director, Asia

Fleming Fund

Toby Leslie

Health Specialist

Fleming Fund